Last deal

$7M

Amount

Series A

Stage

30.11.2021

Date

4

all rounds

$49.5M

Total amount

General

About Company
This company is revolutionizing cancer treatment by educating immune cells and eradicating cancer.

Industry

Sector :

Subsector :

Keywords :

Also Known As

MANA

founded date

18.10.2018

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

Comprised of a dedicated team of scientists, physicians, and advocates, this company is at the forefront of developing next-generation immunotherapies. Their innovative cell therapies provide safer, long-lasting, and cost-effective solutions for cancer treatment. By leveraging clinical cell immune therapies, they effectively eliminate cancer cells, allowing clinicians to concentrate on educating the body's own immune cells to combat the disease. With a mission to confer lifelong immunity to cancer, this company is poised to transform the landscape of cancer treatment.